- Advertisement -
Novo Nordisk, the maker of blockbuster weight-loss drug Wegovy, said on Wednesday it will cut 9,000 jobs in a bid to reignite growth and fend off intense competition from U.S. rival Eli Lilly and a wave of compounded copycat drugs.
The restructuring, expected to save 8 billion Danish crowns ($1.25 billion) annually, comes as Novo Nordisk faces slowing momentum in its once-booming obesity and diabetes franchises.
The Danish company also issued its third profit warning this year, citing 9…
